PRESS
Photo from The New York Times
|
The New York Times
Why a Century-Old Vaccine Offers New Hope Against PathogensThe century-old BCG tuberculosis vaccine, accessible to billions, trusted by billions, and which costs only 15 cents a dose, shows 92% efficacy against COVID-19 in very small clinical trial by Professor Denise Faustman of Harvard Medical School. It is thought that the vaccine boosts the overall immune system. This exemplifies OSPF's 2+ year exploration of certain off patent vaccines, including BCG, against COVID-19, future pandemics and other diseases - a new scientific and legal/economic paradigm for vaccines. We cannot guarantee that they will work, but we absolutely must explore them. The New York Times article mentions OSPF. "“Imagine if we could use existing vaccines to curb pandemics — that would change world history,” Mr. Menon said."
|
|
Neglected/Infectious Disease Knowledge GraphsOpen Source Pharma Foundation and Ingentium are collaborating on the implementation of an open information commons for the collaborative development of new disease treatments using an open source methodology, initially focusing on tuberculosis, Chikungunya, and Nipah virus.
|
Centers in Bangalore, Paris, and New York
Discovering the Person Who Will Discover the Molecule
|
|
PHASE 3 OPEN SOURCE COVID-19 VACCINE CLINICAL TRIAL
OSPF is a collaborator in a Phase 3 COVID-19 vaccine trial in Brazil, testing the efficacy of the off-patent MMR vaccine and of the low-cost influenza vaccine against the Gamma SARS-CoV-2 variant. The trial has commenced, with 6000 participants across three arms. Co-PI’s Prof. Mihai Netea, Radboud University, Netherlands, and Prof. Sergio Henrique Nascente Costa, Federal University of Goias. Brazil. Protocol summary here.
